Myriad myRisk®

Manage Future Cancer Risk, Inform Treatment Decisions Related to PARP Inhibitors 1

 Blending both genetic test status and personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. In addition, myRisk’s assessment of the BRCA1 and BRCA2 genes can help inform treatment decisions related to PARP inhibitor therapy.1

Inform Treatment Decisions Manager Future Cancer Risk
  • Knowing BRCA1 and BRCA2 status may inform treatment decisions related to PARP inhibitors
  • In the OlympiAD trial of patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, the risk of progression or death was 42% lower with olaparib monotherapy than with standard therapy1
  • Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk
  • First-degree relatives of these patients are at a 50% risk for carrying the mutation.
  • Those relatives who are positive may benefit from increased surveillance and/or preventive measures.
Learn More About the OlympiAD Trial Learn More About Future Cancer Risk for Your Patients and Their Families

Stay Informed! Sign up for Companion Diagnostic Emails

Ready to Get Started? ORDER A TEST KIT NOW



1. Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 10.1056/NEJMoa1706450